Qubigen Leaders to Speak at University of Melbourne Computational AI Drug Discovery & Development Workshop
- David Brooks
- Oct 10
- 2 min read
Qubigen is pleased to announce that CEO Dr. Jonathan Hall and CIO A/Prof. Jun Zeng will be featured speakers at the Computational AI Drug Discovery and Development Workshop, hosted by the Bio21 Institute and the Department of Biochemistry and Pharmacology at the University of Melbourne. The event brings together researchers from across the University of Melbourne who are engaged or interested in AI-driven drug discovery.
Date | Monday, October 20, 2025 |
Time | 1.00-5.00 PM |
Location | Bio21 Auditorium, University of Melbourne 30 Flemington Rd, Parkville VIC 3052, Australia. |
Session | Drug Discovery x Federated AI → Accelerating Drug Design |
The intention of the workshop is to strategize how AI can enhance UoM’s drug discovery pipeline by integrating computational techniques into the institution’s existing drug programs. The seminar will feature a series of short presentations from researchers involved in Computational AI Discovery, Development, and Design (CADD), each positioned along the drug development pipeline. Key discussions will explore how computational and wet-lab research teams can effectively integrate their efforts to expand academic-industry partnership opportunities.
Dr. Jonathan Hall and A/Prof. Jun Zeng from Qubigen will jointly present with Prof. Lachlan Coin from the Peter Doherty Institute for Infection and Immunity on the theme of “Drug Discovery x Federated AI → Accelerating Drug Design”. Qubigen will share insights from its Federated AI platform, which enables secure collaboration between institutions and industry partners to generate adjustable novel lead candidates. Qubigen is proud to support this initiative to advance the application of AI in intelligent drug design.
Qubigen is actively seeking collaborators, clients, and partnerships with organizations interested in leveraging Federated AI for drug design. Qubigen invites workshop attendees to connect with Dr. Hall or A/Prof. Zeng during the event to discuss opportunities.
Qubigen: accelerate drug design without exposing secrets
Whether you're advancing active programs, reviving dormant data, or starting from scratch, Qubigen’s secure AI platform and virtual screening capabilities can help you identify, optimize, and accelerate the path to promising lead drug candidates. Get in touch to explore how we can support your next development.
